← Leaderboards
Raymond A. Chavez
Xalud Therapeutics, Inc.
$3,536,823
Attributed
$3,536,823
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2011–14$2M$1.5M$1M$500K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$3,536,823 · 2
By mechanism
U44$2,847,606 · 1
R43$689,217 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyAnti-Inflammatory AgentsNeuronsRattusSpinalToxicologyGene TherapyIntrathecal InjectionsPainful NeuropathyProductionSeriesCytokineSpinal CordTissuesAffectClinical TrialsInflammatoryInterleukin-10Autoimmune ProcessAnti-InflammatoryBasePlasmid DnaDisease ModelAmerican
Grant awards (7)
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$383,748
U44 · FY2014 · NS · contact PI
XT-101: A Potent IL-10 Based Therapy for Treating Multiple Sclerosis.$350,000
R43 · FY2014 · NS · contact PI
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$216,354
U44 · FY2014 · NS · contact PI
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$951,688
U44 · FY2013 · NS · contact PI
XT-101: A Potent IL-10 Based Therapy for Treating Multiple Sclerosis.$339,217
R43 · FY2013 · NS · contact PI
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$996,485
U44 · FY2012 · NS · contact PI
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$299,331
U44 · FY2011 · NS · contact PI